



Balfour Capital Group BioNTech SE

BioNTech SE is a biotechnology company specializing in the development of immunotherapies for cancer and infectious diseases. The company's product portfolio includes investigational mRNA vaccines, protein-based therapeutics, cell therapies, and small molecules. BioNTech collaborates with multiple global pharmaceutical companies, including Pfizer, to develop mRNA-based vaccines.

1. Top 5 Competitors

BioNTech's primary competitors include:

- GSK (GlaxoSmithKline)
- Takeda Pharmaceutical
- argenx
- BeiGene
- Teva Pharmaceutical Industries

These companies are part of the pharmaceutical products industry and compete in similar therapeutic areas.

2. Largest Institutional Shareholders

As of the latest available data, major institutional shareholders of BioNTech include:

- AT Impf GmbH: 43.8% ownership
- Ugur Sahin (Co-Founder and CEO): 17.4% ownership
- Baillie Gifford & Co.: 3.66% ownership
- PRIMECAP Management Company: 2% ownership
- Temasek Holdings (Private) Limited: 1.9% ownership

3. Management Team:

Key members of BioNTech's management team include:

- Ugur Sahin: Co-Founder and Chief Executive Officer
- Jens Holstein: Chief Financial Officer
- Sean Marett: Chief Business and Chief Commercial Officer
- Sierk Poetting: Chief Operating Officer



Balfour Capital Group BioNTech SE

4. Revenue

BioNTech's annual revenues have fluctuated significantly in recent years:

- 2021: Approximately €19 billion
- 2022: Approximately €17.3 billion
- 2023: Approximately €3.8 billion

The substantial revenue in 2021 and 2022 was primarily due to the global demand for COVID-19 vaccines. The decline in 2023 reflects the reduced demand as the pandemic subsided.

5. Institutions with Buy Recommendations:

As of March 2025, analysts have shown optimism toward BioNTech:

- Jefferies: Upgraded BioNTech to a "Buy" rating with a price target of \$150.
- Leerink Partners: Assigned an "Outperform" rating, indicating a positive outlook.

6. Summary of Analyst Sentiment:

Analysts have a favorable view of BioNTech's prospects:

- Strong Buy consensus rating based on 11 Buy and 2 Hold recommendations.
- Average price target: \$142.86, suggesting potential upside.

7. Insider Buying and Selling Over the Last 24 Months:

- Over the past two years, there has been notable insider activity:
 - Insider Sales: Corporate insiders sold shares worth approximately \$140.2 million in the last three months.
 - Notable Transactions: In February 2025, CEO Ugur Sahin sold shares worth approximately \$119 million.

Please note that financial figures and insider activities are subject to change. For the most current information, it's advisable to consult BioNTech's official investor relations and recent filings with regulatory authorities.